MAHOGANY: A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Condition: Follicular Lymphoma or Marginal Zone Lymphoma
Sponsor: BeOne Medicines
Full Title
Protocol BGB-3111-308: A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Study Treatment
Follicular Lymphoma: Zanubrutinib + Obinutuzumab vs Lenalidomide + Rituximab
Marginal Zone Lymphoma: Zanubrutinib + Rituximab vs Lenalidomide + Rituximab
Eligibility/Info
- Classic follicular lymphoma or marginal zone lymphoma
- Previous treatment with at least 1 line of therapy including an anti-CD20 monoclonal antibody
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
